ImmunityBio amends $505M convertible note to allow partial conversion at any time

ImmunityBio, Inc.

Convertible note amendment allows holder Nant Capital to convert any portion of $505M principal into common stock at any time before maturity.
Previously, partial conversion was not permitted under the December 2024 note; no other terms changed.
Holder Nant Capital is an affiliate of Executive Chairman Dr. Patrick Soon-Shiong, making this a related-party transaction.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ImmunityBio, Inc. amended Convertible Note Amendment with Nant Capital, LLC (effective 2026-01-23).

Action: amendment
Agreement: notes offering
Counterparty: Nant Capital, LLC
Effective: 2026-01-23

Exact text from the filing

On January 23, 2026, ImmunityBio, Inc. (the “Company”) entered into a letter amendment (the “Convertible Note Amendment”) to that certain convertible Second Amended and Restated Promissory Note, dated December 10, 2024, in an outstanding principal amount of $505.0 million (the “Convertible Promissory Note”), by and among the Company and Nant Capital, LLC (the “Holder”), an entity affiliated with Dr. Patrick Soon-Shiong, the Company’s Executive Chairman and Global Chief Scientific and Medical Officer.

View on SEC.gov

306 material agreements filed in the last 30 days. Browse all material agreements →

ImmunityBio, Inc. filing history →

Source: SEC EDGAR

accession 0001326110-26-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.